Dyne Therapeutics, Inc. reported a net loss of $120.9 million for the first quarter of 2026, compared to a net loss of $115.4 million in the same period of 2025. The company's total operating expenses increased slightly to $125.3 million from $122.4 million year-over-year. Research and development expenses decreased to $100.9 million from $106.4 million, while general and administrative expenses rose significantly to $24.4 million from $15.9 million, reflecting increased headcount and associated costs. The net loss per share improved to $(0.73) from $(1.05) as the weighted average shares outstanding increased to 165 million from 110 million.
In terms of financial position, Dyne's cash and cash equivalents decreased to $753.1 million as of March 31, 2026, down from $893.4 million at the end of 2025. The company also reported total assets of $1.08 billion, a decline from $1.19 billion at the end of the previous fiscal year. The accumulated deficit increased to $1.52 billion, reflecting ongoing investment in research and development without any revenue generation, as the company has not yet commercialized any products.
Operationally, Dyne is advancing its clinical programs, particularly for its lead product candidates, z-rostudirsen and z-basivarsen, which target Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), respectively. The company is preparing for a biologics license application (BLA) submission for z-rostudirsen in the second quarter of 2026, with a potential U.S. launch anticipated in early 2027. The company has also initiated a global Phase 3 clinical trial for z-rostudirsen and is progressing with the HARMONIA trial for z-basivarsen.
Looking ahead, Dyne Therapeutics expects to continue incurring significant operating losses as it advances its product candidates through clinical trials and expands its research efforts. The company anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the first quarter of 2028. However, it acknowledges the need for substantial additional funding to support ongoing development and commercialization efforts, which may include equity offerings, debt financing, and strategic collaborations. The company remains focused on its goal of delivering functional improvements for patients with genetically driven neuromuscular diseases.
About Dyne Therapeutics, Inc.
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for neuromuscular and genetic muscle diseases. Utilizing its proprietary FORCE platform, it creates conjugates of antibodies, linkers, and payloads—such as oligonucleotides and enzymes—to deliver disease-modifying treatments to muscle tissue and the CNS. Its portfolio includes therapies for DM1, DMD, FSHD, and Pompe disease, focusing on genetic targets with high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.